Menu

Press Releases

U.S. FDA Approves Gilead’s Once-Daily Single Tablet HIV-1 Regimen Complera® for Patients Switching from a Stable Regimen

, , , ,

— European Commission Also Approves Expanded Indication for Regimen, Marketed as Eviplera® in the European Union — FOSTER CITY, Calif.–(BUSINESS WIRE)–Dec. 13, 2013– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the single tablet HIV-1 regimen Complera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable […]

Merck Advances Development Program for Investigational Alzheimer’s Disease Therapy, MK-8931

, , , ,

Data Monitoring Committee recommends continuation of Phase II/III EPOCH study in mild to moderate disease patients Merck also plans to initiate dosing in Phase III study of prodromal disease patients WHITEHOUSE STATION, N.J. December 10, 2013 — (BUSINESS WIRE) –Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on the […]

Sangamo BioSciences Presents Data From Non-Human Primates Providing Proof Of Concept For Disruptive And Broadly Leverageable Platform For Protein Replacement Therapies

, , ,

Data Presented at American Society of Hematology (ASH) Meeting Demonstrates Therapeutic Levels of Gene Modification in Sangamo’s In Vivo Protein Replacement Platform RICHMOND, Calif., Dec. 10, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new pre-clinical data demonstrating therapeutic levels of gene modification in non-human primates (NHPs) from its In Vivo Protein Replacement Platform. Based […]

Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting

, , ,

Novel Genome-Editing Approach Offers a Potential Cure for Both Diseases RICHMOND, Calif., Dec. 9, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of preclinical data from its ZFP Therapeutic program for the treatment and potential cure of both sickle cell disease (SCD) and beta-thalassemia. The data demonstrate that Sangamo’s approach, using its proprietary and highly specific […]

New Phase 3 Data Confirm Long-Lasting Characteristics Of ALPROLIX™ and ELOCTATE™ Across Multiple Hemophilia Populations

, , ,

– Interim Analyses from Phase 3 Pediatric Studies Suggest Prolonged Half-Life of Investigational Long-Lasting Therapies in Children Under Age 12 – CAMBRIDGE, Mass. & STOCKHOLM–(December 9, 2013)–Today Biogen Idec (NASDAQ:BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) announced new results from Phase 3 studies of their investigational long-lasting recombinant factor IX and VIII Fc fusion protein candidates for […]

American Medical Systems Receives FDA 510(k) Clearance of the RetroArc™ Retropubic Sling System for Treatment of Female Stress Urinary Incontinence

, , ,

RetroArc Extends the AMS™ Continence Sling Portfolio to Provide More Options for Women With SUI MINNEAPOLIS, Dec. 9, 2013 /PRNewswire/ — American Medical Systems® Inc. (AMS), an Endo Health Solutions Inc. (Nasdaq: ENDP)  subsidiary and leading provider of devices and therapies for male and female pelvic health, today announced FDA 510(k) Clearance of its RetroArc™ Retropubic Sling System for treatment of female stress […]

Forest Laboratories Announces Appointments to its Executive Team

, , ,

NEW YORK– December 9, 2013 — (BUSINESS WIRE) –Forest Laboratories, Inc. (NYSE:FRX) today announced appointments to its executive leadership team. The appointments are part of Forest’s announced plans to flatten and broaden the organization as part of Project Rejuvenate. “Today we are announcing an important step to rejuvenate our company by creating the first Forest Executive Team […]

Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin’s Lymphoma

, , , ,

57 Percent Overall Response Rate and Median Duration of Response of 12.5 Months in Heavily Pre-Treated Patients Data Presented at American Society of Hematology Annual Meeting NEW ORLEANS, Dec 08, 2013 (BUSINESS WIRE) –Gilead Sciences, Inc. (Nasdaq: GILD) today announced results of a Phase 2 study (Study 101-09) evaluating idelalisib, an investigational oral inhibitor of PI3K […]

Gilead Announces Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia

, , , ,

Data Presented at the 55th American Society of Hematology Annual Meeting NEW ORLEANS–(BUSINESS WIRE)–Dec. 7, 2013– Gilead Sciences, Inc. (Nasdaq: GILD) today announced interim results from a single-arm, open-label Phase 2 study evaluating GS-9973, an investigational oral inhibitor of spleen tyrosine kinase (Syk), for the treatment of patients with relapsed or refractory hematologic malignancies. The data show that […]

«‹ 93 94 95 96›»